Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

Murray Esler, Henry Krum, Paul A Sobotka, Markus P Schlaich, Roland E Schmieder, Michael Bohm, Felix Mahfoud, Horst Sievert, Nina Wunderlich, Lars C Rump, Oliver Vonend, Michael Uder, Mel D Lobo, Mark J Caulfield, Andrejs Erglis, Michel Azizi, Marc Sapoval, Suku Thambar, Alexandre Persu, Jean P M RenkinHeribert Schunkert, Joachim Weil, Uta C Hoppe, Antony Walton, Dierk Scheinert, Thomas Binder, Andrzej Januszewicz, Adam Witkowski, Luis Miguel Ruilope, Robert Whitbourn, Heike Bruck, Mark O Downes, Thomas F Luscher, Alan G M Jardine, Mark W Webster, Thomas Zeller, Jerzy Sadowski, Krzysztof Bartus, Craig A Straley, Neil Barman, David P Lee, Ronald M Witteles, Vivek Bhalla, Joseph M Massaro

Research output: Contribution to journalArticleResearchpeer-review

1756 Citations (Scopus)

Abstract

In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (?150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months
Original languageEnglish
Pages (from-to)1903 - 1909
Number of pages7
JournalThe Lancet
Volume376
Issue number9756
DOIs
Publication statusPublished - 2010

Cite this